Last update 01 Nov 2024

Rencofilstat

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Cyclosporine A analogue
+ [1]
Mechanism
CYPA inhibitors(Cyclophilin A inhibitors), Hepatitis B structural protein inhibitors
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC67H122N12O13
InChIKeyKBARHGHBFILILC-NGIJKBHDSA-N
CAS Registry1383420-08-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrosis, LiverPhase 2
US
23 Jun 2020
Multiple MyelomaPreclinical
US
18 Jan 2023
Fibrosis, LiverPreclinical
PR
23 Jun 2020
Nonalcoholic SteatohepatitisPreclinical
PR
23 Jun 2020
Nonalcoholic SteatohepatitisPreclinical
US
23 Jun 2020
Bacterial InfectionsPreclinical
US
09 Jul 2019
Hepatitis BPreclinical
US
09 Jul 2019
Nonalcoholic SteatohepatitisDiscovery
PR
23 Jun 2020
Nonalcoholic SteatohepatitisDiscovery
US
23 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(zbchnvbsye) = 38 treatment-related AEs in the trial. No subjects discontinued the trial due to treatment-related AE, and only 1 treatment-related AE was > Grade 2 xvditmeqrw (xcpifzwkbl )
Positive
04 Jan 2024
Phase 2
-
(ojunzstunk) = zedguekgxu vifpukaell (ikjqyspdbh, -44.3 to -13.4)
Positive
13 Nov 2023
Phase 2
Nonalcoholic Steatohepatitis
transaminases | ELF-score | Pro-C3 ...
43
(iergggndeg) = hhnjcpehij emlrjddhpy (pnfwuarnbf )
Positive
06 Jan 2022
(iergggndeg) = xjphmcjdnj emlrjddhpy (pnfwuarnbf )
Not Applicable
-
-
nggpjtrlld(fzqtyflqop) = kxcozgnzbj xzjykvcofo (grjixeogiu )
Positive
09 Jan 2020
Phase 1
HBV DNA | HBsAg | HBeAg ...
32
qgtzebqjxw(ygrgeqsuaq) = Safety results demonstrated that CRV431 was well tolerated with no serious adverse events (SAE), no dose-limiting toxicities or dose-dependent adverse events. Overall, the incidence of adverse events and laboratory abnormalities was low and similar among cohorts. All AEs were mild and not drug related. moojfftcye (kwlwzdwfvm )
Positive
12 Apr 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free